Skip to content
ESPT
MARKETS / NASDAQ / Industrials / Engineering and consulting / NRC
NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · MID CAP

NRC Health NRC

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$137.4M
▼ 4.0% YoY
$11.6M
▼ 53.2% YoY
$15.7M
▼ 17.9% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The company's portfolio of subscription-based solutions provides information, analysis, and workflow enablement tools to healthcare organizations covering patient experience, service recovery, care transitions, employee engagement, reputation management, rounding, and brand loyalty. Its ten largest customers collectively accounted for 20% of total revenue in 2025, compared with 17% in 2024 and 15% in 2023. As of December 31, 2025, the company employed a total of 357 associates. Its digital solutions consist of four primary solution categories — Patient Experience, Consumer Experience, Employee Experience, and Market Experience — which can be implemented collectively as an enterprise solution or individually to meet specific needs within the organization. Its Market Insights survey measures the opinions and behaviors of approximately 300,000 healthcare consumers across the contiguous United States annually. The company was founded in 1981 and has grown through internal product development as well as select acquisitions. It is a Delaware corporation headquartered in Lincoln, Nebraska.

Written from the business description in NRC HEALTH's annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth

USD 137.4M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 137.4 · Net income 11.6
100M200M
2009201220152018202120242025
Compound annual growth
−3.2%
+0.6%
+3.0%
+5.3%
−28.5%
−20.8%
+240.2%
+103.0%
−14.8%
+19.9%
−13.9%
+24.2%
+10.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 16.4% · Net 8.4%
10%20%30%
200920172025
ROE
FY2018 · ROE 55.1%
20%40%
200920172025
Three returns, three denominators.
Return on equityNot available: we don't have a clean profit figure for this period.
Gross margin61.9%
Operating margin16.4%
Net margin8.4%
EBITDA·

Return on equity has no reading this year — return on capital employed, just below, still does: 23%.

Cash & shareholders

USD 31.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 15.7
15M30M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends 11.0 · Net buybacks 20.0
20M40MDividendsNet buybacks
200920112013201620182020202220242025
Dividends paidUSD 11.0M
Net buybacksUSD 20.0M
Share of profit·
Consecutive raises1 year

USD 11.0M in dividends and USD 20.0M in buybacks — Not available: we don't have a clean profit figure for this period.

Total assetsUSD 134.9M
EquityUSD 14.0M
CashUSD 4.1M
Gross debtUSD 75.0M
Net debtUSD 70.9M
Current ratio0.55×

Net debt stands at 507% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

The share count changed between 2012 and 2017, but the exact year can't be marked here — the underlying count wasn't on file for every year in that stretch.

row low → row highnegative—not applicable◌not available in our data
NRC, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.10.10.20.10.10.10.10.10.10.10.10.10.10.10.10.1
Operating income $B0.00.00.00.00.10.00.00.00.00.00.00.00.00.00.00.00.0
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌0.00.00.00.00.00.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Free cash flow $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $50.001.041.251.27◌1.451.26◌◌◌◌◌◌2.171.691.261.26
Dividend / sh $0.520.481.480.840.480.210.78◌◌◌◌◌◌2.540.880.760.64
Payout %◌◌◌◌◌◌◌567413957—14115514450
ROE %◌◌◌◌◌◌◌55.126.526.121.722.824.126.822.224.919.2
Shares out B0.020.020.020.020.030.030.020.020.02◌◌◌◌0.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

AAPL · F · GM · DELL · TSLA · FDX
Provenance

Company facts, as filed

How we verify · 1 failure in 59 reconciliationsAUDITED

Reconciled in 16 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image